CommercialCoverageLow impact
Scenesse (afamelanotide)
Blue Cross & Blue Shield of Mississippi·MS · Dermatology·Medical Policy
Effective date
Feb 24, 2026
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their policy for Scenesse (afamelanotide) to clarify that both the medication and its administration services are considered not medically necessary for treating erythropoietic protoporphyria. This policy maintains that supportive measures remain the standard treatment approach.
Action Required
Immediately: Billing team should verify that HCPCS code J7352 (afamelanotide implant) is flagged as non-covered in billing system for BCBS Mississippi patients. Ensure claims for this medication and related administration services are not submitted, as they will be denied. Update prior authorization systems to reflect not medically necessary status.